In this issue of PRM we are provided with an exciting and timely update on emerging diagnostic or prognostic biomarkers and therapeutic approaches for lung cancer. Recent approaches include novel targeting of angiogenic factors including Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) produced by Non-Small Cell Lung Carcinoma (NSCLC). VEGF is known to promote the vascularization and growth of the tumor by mobilizing circulating endothelial cell precursors to the nascent blood vessels and plays a key role in establishing new metastatic foci. bFGF in addition to its involvement in tumor growth, may have the potential to predict early-stage NSLC recurrence following tumor resection. Ghany et al. [3] in the article that accompanies this commentary, report that Nimesulide, an antiangiogenic selective COX-2 inhibitor, showed promising results as an add-on therapy with traditional chemotherapy. Levels of pro-angiogenic parameters were normalized, potentially having a positive effect on the outcome and prolongation of survival rate in patients with NSLC.